

1/27

FIG. 1

Panel A:

Clone ID	CDR1	CDR2	CDR3	V-Gene	J-Gene
309157 (CD38-F11A)	GFTFSSYG (SEQ ID NO: 1)	ISDDGSNK (SEQ ID NO: 6)	AKDRGTMRVVVYD TLDI (SEQ ID NO: 13)	IGHV3-30*18	IGHJ1*01
Consensus Sequence (nt FR1-FR4)	CAGGTGCAGCTGGTGGAGTCGGGGGAGGCGTGGT CCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGC CTCTGGATTACCTTCAGTAGCTATGGCATGCACTGG GTCCGCCAGGCTCCAGGCAAGGAGCGGGAGTGGGTG GCAGTTATATCAGATGATGGAAGTAATAAATATTATG CAGACTCCGTGAAGGGCCGATTACCATCTCCAGAGA CAATTCCAAGAACACGCTGTATCTCCAAATGAACAGC CTGAGAGTTGAGGACACGGCTGTGTATTACTGTGCGA AAGATCGGGGTACTATGAGAGTAGTGGTTTATGATAC TTTGGATATCTGGGGCCAGGGCACCTGGTCACCGTC TCCTCA (SEQ ID NO: 32)			Percent CD38 Hydrolase Inhibition	24
Consensus Sequence (aa FR1-FR4)	QVQLVESGGGVVQPGRSLRLSCAAS GFTFSSYGMHWVRQAPGKEREWVA VISDDGSNKYYADSVKGRFTISRDN KNTLYLQMNSLRVEDTAVYYCAKD RGTMRVVYDITLDIWGQGLTVTVSS (SEQ ID NO: 18)			Cell Binding MFI	5201

Panel B:

Clone ID	CDR1	CDR2	CDR3	V-Gene	J-Gene
309159 (CD38-F11B)	GFTFSSYG (SEQ ID NO: 1)	ISDDGSNK (SEQ ID NO: 6)	AKDRGTMRVAVYD AFDL (SEQ ID NO: 14)	IGHV3-30*18	IGHJ1*01
Consensus Sequence (nt FR1-FR4)	GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCGTGGT CCAGCCTGGGAGGTCCCTGAGACTCTCTTGTGCAG CCTCTGGATTACCTTCAGTAGCTATGGCATGCACT GGGTCCGCCAGGCTCCAGGCAAGGAGCGGGAGTGG GTGGCAGTTATATCAGATGATGGAAGTAATAAATA CTATGCAGACTCCGTGAAGGGCCGATTACCATCTC CAGAGACAATTCCAAGAACACGCTGTATCTGCAAAT GAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTA CTGTGCGAAAGATCGGGGTACTATGAGAGTAGCGGT TTATGATGCTTTTGATCTCTGGGGCCAGGGCACCTG GTCACCGTCTCCTCA (SEQ ID NO: 33)			Percent CD38 Hydrolase Inhibition	ND
Consensus Sequence (aa FR1-FR4)	EVQLLESGGGVVQPGRSLRLSCAASG FTFSSYGMHWVRQAPGKEREWVAVIS DDGSNKYYADSVKGRFTISRDNKNTL YLQMNSLRAEDTAVYYCAKDRGTMRV AVYDAFDLWGQGLTVTVSS (SEQ ID NO: 19)			Cell Binding MFI	ND

SUBSTITUTE SHEET (RULE 26)

2/27

FIG. 1, Cont.

Panel C:

Clone ID	CDR1	CDR2	CDR3	V-Gene	J-Gene
350191 (CD38-F11C)	GFTFSSYG (SEQ ID NO: 1)	ISDDGSNK (SEQ ID NO: 6)	AKDRGTMRVAVYD TLDI (SEQ ID NO: 15)	IGHV3-30*18	IGHJ1*01
Consensus Sequence (nt FR1-FR4)	CAGGTGCAGCTGGTGGAGTCGGGGGAGGCGTG GTCCAGCCTGGGAGGTCCCTGACACTCTCCTGTG CAGCCTCTGGATTACCTTCAGTAGCTATGGCAT GCACTGGGTCCGCCAGGCTCCAGGCAAGGAGCG GGAGTGGGTGGCAGTTATATCAGATGATGGAAG TAATAAATATTATGCAGACTCCGTGAAGGGCCG ATTCACCATCTCCAGAGACAATTCCAAGAACAC GCTGTATCTGCAAATGAACAGCCTGAGAGTTGA GGACACGGCTGTGTATTACTGTGCGAAAGATCG GGGTACTATGAGAGTAGCGGTTTATGATACTTTG GATATCTGGGGCCAGGGCACCTGGTCACCGTCT CCTCA (SEQ ID NO: 34)			Percent CD38 Hydrolase Inhibition	25
Consensus Sequence (aa FR1-FR4)	QVQLVESGGGVVQPGRSLTLSCAASGFTFSS YGMHWVRQAPGKEREWVAVISDDGSNKYY ADSVKGRFTISRDN SKNTLYLQMNSLRVEDT AVYYCAKDRGTMRVAVYDTLDIWGQGTLV TVSS (SEQ ID NO: 20)			Cell Binding MFI	5480

Panel D:

Clone ID	CDR1	CDR2	CDR3	V-Gene	J-Gene
350210 (CD38-F11D)	GFTFSSYG (SEQ ID NO: 1)	ISYDGSKK (SEQ ID NO: 7)	AKDRGTMRVVYDT LDI (SEQ ID NO: 13)	IGHV3-30*18	IGHJ1*01
Consensus Sequence (nt FR1-FR4)	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTC CAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCT CTGGATTACCTTCAGTAGCTATGGCATGCACTGGGT CCGCCAGGCTCCAGGCAAGGAGCGGGAGTGGGTGGC AGTTATATCATATGATGGAAGTAAGAAATACTATGC AGACTCCGTGAAGGGCCGATTACCATTCTCCAGAGA CAATTC AAGAACACGCTGTATCTCAAATGAACAG CCTGAGAGTTGAGGACACGGCTGTGTATTACTGTGC GAAAGATCGGGTACTATGAGAGTAGTGGTTTATGA TACTTTGGATATCTGGGGCCAGGGCACCTGGTCACC GTCTCCTCA (SEQ ID NO: 35)			Percent CD38 Hydrolase Inhibition	35
Consensus Sequence (aa FR1-FR4)	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG MHWVRQAPGKEREWVAVISYDGSKKYYADSV KGRFTISRDN SKNTLYLQMNSLRVEDTAVYYCA KDRGTMRVVYDTLDIWGQGTLVTVSS (SEQ ID NO: 21)			Cell Binding MFI	4089

SUBSTITUTE SHEET (RULE 26)

3/27

FIG. 1, Cont.

Panel E:

Clone ID	CDR1	CDR2	CDR3	V-Gene	J-Gene
350250 (CD38-F11E)	GFTFSGYG (SEQ ID NO: 2)	ISYDGSNK (SEQ ID NO: 8)	AKDRGTMRVVVD TLDI (SEQ ID NO: 13)	IGHV3- 30*18	IGHJ1*0 1
Consensus Sequence (nt FR1- FR4)	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTT GGTACAGCCTGGGGGGTCCCTGAGACTCTCCTG TGCAGCCTCTGGATTCACCTTCAGTGGCTATGG CATGCACTGGCTCCGCCAGGCTCCAGGCAAGGA GCGGGAGTGGGTGGCAGTTATATCATATGATGG AAGTAATAAATACTATGCAGACTCCGTGAAGGG CCGATTCACCATCTCCAGAGACAATTCCAAGAAC ACGCTGTATCTCCAAATGAACAGCCTGAGAGTTG AGGACACGGCTGTGTATTACTGTGCGAAAGATCG GGGTACTATGAGAGTAGTGGTTTATGATACTTTGG ATATCTGGGGCCAGGGCACCTGGTCACCGTCTC CTCA (SEQ ID NO: 36)			Percent CD38 Hydrolase Inhibition	32
Consensus Sequence (aa FR1- FR4)	QVQLVESGGGLVQPGGSLRLSCAASGFTFSGY GMHWLRQAPGKEREWVAVISYDGSNKYYAD SVKGRFTISRDN SKNTLYLQMNSLRVEDTAVY YCAKDRGTMRVVVDTLDIWGQGTLVTVSS (SEQ ID NO: 22)			Cell Binding MFI	5240

4/27

FIG. 2

Panel A:

Clone ID	CDR1	CDR2	CDR3	V-Gene	J-Gene
330304 (CD38-F12A)	GFTFSSSW (SEQ ID NO: 3)	IKQDGSEK (SEQ ID NO: 9)	ARDRRGPFHHI (SEQ ID NO: 16)	IGHV3-7*01	IGHJ1*01
Consensus Sequence (nt FR1-FR4)	GGGGTGCAGCTGGTGGAGTCTGGGGGAGGC TTGGTCCAGCCTGGGGGGTCCCTGAGACTCT CCTGTACAGCCTCTGGATTACCTTTAGTAGC TCTTGATGAGCTGGGTCCGCCAGGCTCCAGG GAAGGGGCTGGAATGGGTGGCCAACATAAAG CAAGATGGAAGTGAGAAAGACTATGTGGACT CTGCGAAGGGCCGATTACCATCTCCAGAGAC AACGCCAAGAACTCACTGTATCTGCAAATGAA CAACCTGAGAGCCGAGGACACGGCTGTGTATT ACTGTGCGAGAGATAGGAGGGGGCCCTTTTTTC ATATCTGGGGCCAGGGCACCTGGTCACCGTCT CCTCA (SEQ ID NO: 37)			Percent CD38 Hydrolase Inhibition	40
Consensus Sequence (aa FR1-FR4)	GVQLVESGGGLVQPGGSLRLSCTASGFTFSSS WMSWVRQAPGKGLEWVANIKQDGSEKDYV DSAKGRFTISRDNANKSLYLQMNLR AEDTA VYYCARDRRGPFHHIWGQGLTVTVSS (SEQ ID NO: 23)			Cell Binding MFI	5554

Panel B:

Clone ID	CDR1	CDR2	CDR3	V-Gene	J-Gene
330484 (CD38-F12B)	GFTFSSSW (SEQ ID NO: 3)	IKQDGSEK (SEQ ID NO: 9)	ARDRRGPFHHI (SEQ ID NO: 16)	IGHV3-7*01	IGHJ1*01
Consensus Sequence (nt FR1-FR4)	GGGGTGCAGCTGGTGGAGTCTGGGGGAGGCT TGGTCCAGCCTGGGGGGTCCCTGAGACTCTCC TGTGCAGCCTCTGGATTACCTTTAGTAGCTC TTGGATGAGCTGGGTCCGCCAGGCTCCAGGG AAGGGGCTGGAATGGGTGGCCAACATAAAGC AAGATGGAAGTGAGAAAGACTATGTGGACTC TGCGAAGGGCCGATTACCATCTCCAGAGACA ACGCCAAGAACTCACTGTATCTGCAAATGAACA ACCTGAGAGCCGAGGACACGGCTGTGTATTACT GTGCGAGAGATAGGAGGGGGCCCTTTTTTCATA TCTGGGGCCAGGGCACCTGGTCACCGTCTC CTCA (SEQ ID NO: 38)			Percent CD38 Hydrolase Inhibition	50
Consensus Sequence (aa FR1-FR4)	GVQLVESGGGLVQPGGSLRLSCAASGFTFSSS WMSWVRQAPGKGLEWVANIKQDGSEKDYVD SAKGRFTISRDNANKSLYLQMNLR AEDTAVY YCARDRRGPFHHIWGQGLTVTVSS (SEQ ID NO: 24)			Cell Binding MFI	ND

SUBSTITUTE SHEET (RULE 26)

5/27

FIG. 2, Cont.

Panel C:

Clone ID	CDR1	CDR2	CDR3	V-Gene	J-Gene
350313 (CD38-F12C)	GFTFSSSW (SEQ ID NO: 3)	INQDGSEK (SEQ ID NO: 10)	ARDRRGPFHI (SEQ ID NO: 16)	IGHV3-7*01	IGHJ1*01
Consensus Sequence (nt FR1-FR4)	GGGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTACCTTTAGTAGCTCTTGGATGAGCTGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAATGGGTGGCCAACATAAACCAAGATGGAAGTGAGAAAGACTATGTGGACTCTGCGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGTCGAGGACACGGCTGTGTATTACTGTGCGAGAGATAGGAGGGGGCCCTTTTTCATATCTGGGGCCAGGGCACCTGGTCAACCGTCTCCTCA (SEQ ID NO: 39)			Percent CD38 Hydrolase Inhibition	45
Consensus Sequence (aa FR1-FR4)	GVQLVESGGGLVQPGGSLRLSCAASGFTFSSSWMSWVRQAPGKGLEWVANINQDGSEKDYVDSAKGRFTISRDNKNSLYLQMNSLRVEDTAVYYCARDRRGPFFHIWGQGLTVTVSS (SEQ ID NO: 25)			Cell Binding MFI	5984

Panel D:

Clone ID	CDR1	CDR2	CDR3	V-Gene	J-Gene
350337 (CD38-F12D)	GFTFSSSW (SEQ ID NO: 3)	IKQDGSEK (SEQ ID NO: 9)	ARDRRGPFHI (SEQ ID NO: 16)	IGHV3-7*03	IGHJ1*01
Consensus Sequence (nt FR1-FR4)	GGGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTACCTTTAGTAGCTCTTGGATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAATGGGTGGCCAACATAAAGCAAGATGGAAGTGAGAAAGACTATGTGGACTCTGCGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGACAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGATAGGAGGGGGCCCTTTTTCATATCTGGGGCCAGGGCACCTGGTCAACCGTCTCCTCA (SEQ ID NO: 40)			Percent CD38 Hydrolase Inhibition	46
Consensus Sequence (aa FR1-FR4)	GVQLVESGGGLVQPGGSLRLSCAASGFTFSSSWMSWVRQAPGKGLEWVANIKQDGSEKDYVDSAKGRFTISRDNKNSLYLQMNSLTAEDTAVYYCARDRRGPFFHIWGQGLTVTVSS (SEQ ID NO: 26)			Cell Binding MFI	5785

SUBSTITUTE SHEET (RULE 26)

6/27

FIG. 3

Panel A:

Clone ID	CDR1	CDR2	CDR3	V-Gene	J-Gene
330505 (CD38-F13A)	GGSISSSLFY (SEQ ID NO: 4)	IHDSGST (SEQ ID NO: 11)	ARGPRGFYSSGPDDFDI (SEQ ID NO: 17)	IGHV4-39*01	IGHJ1*01
Consensus Sequence (nt FR1-FR4)	CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACT GGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG CACTGTCTCTGGTGGCTCCATCAGTAGTAGTCT TTTCTACTGGGGGTGGATCCGCCAGCCCCCGGG GAAGGGGCTGGAGTGGATTGGGAGTATCCATG ATAGTGGGAGCACCTACTACAACCCGTCCCTCA AGAGTCGAGTCACCATATCCGCAGACACGTCCA AGAACCAGTTCTCCCTGAAGCTGAACCTCTGTGA CCGCCACAGACACGGCTGAGTATTACTGTGCGA GAGGGCCGCGCGGTTTCTATAGCAGTGGCCCTG ATGATTTTGATATCTGGGGCCAGGGCACCTGG TCACCGTCTCCTCA (SEQ ID NO: 41)			Percent CD38 Hydrolase Inhibition	38
Consensus Sequence (aa FR1-FR4)	QLQLQESGPGLVKPSSETLSLTCTVSGSISSSLFY WGWIQQPGKGLEWIGSIHDSGSTYYNPSLKSRV TISADTSKNQFSLKLNSVTATDTAEYYCARGPRG FYSSGPDDFDIWGQGTTLVTVSS (SEQ ID NO: 27)			Cell Binding MFI	1296

Panel B:

Clone ID	CDR1	CDR2	CDR3	V-Gene	J-Gene
339296 (CD38-F13B)	GGSISSSNYH (SEQ ID NO: 5)	IYYSGST (SEQ ID NO: 12)	ARGPRGFYSSGPDDFDI (SEQ ID NO: 17)	IGHV4-39*01	IGHJ1*01
Consensus Sequence (nt FR1-FR4)	CAGCTGCAGCTGCAGGAGTCGGGCCCAGGAC TGGTGAAGTCTTCGGAGACCCTGTCCCTCACC TGCATTGTCTCTGGTGGCTCCATCAGCAGTAG TAATTACCACTGGGGCTGGAGCCGCCAGCCCC CAGGGAAGGGGCAGGAGTGGATCGGGAGTAT CTATTACAGTGGAAGTACCTACTACAACCCGT CCCTCAAGAGTCGAGTCACCATTTCCGGAGAC ACGTCCAAGAACCAGTTCTCCCTGAAGCTGAG CTCTGTGACCGCCGCAGACACGGCTGTGTATTA CTGTGCGAGAGGGCCGCGCGGTTTCTATAGCAG TGGCCCTGATGATTTTGATATCTGGGGCCAGGG CACCTGGTCACCGTCTCCTCA (SEQ ID NO: 42)			Percent CD38 Hydrolase Inhibition	0
Consensus Sequence (aa FR1-FR4)	QLQLQESGPGLVKSSETLSLTCTVSGSISSSNYH WGWSRQPPGKGQEWIGSIYYSGSTYYNPSLKSR VTISGDTSKNQFSLKLSSVTAADTAVYYCARGPR GFYSSGPDDFDIWGQGTTLVTVSS (SEQ ID NO: 28)			Cell Binding MFI	2974

7/27

FIG. 4

Additional Sequences:

Name	Amino Acid Sequence	SEQ ID NO:
G4S linker (n=1)	GGGGS	SEQ ID NO: 29
G4S linker (n=2)	GGGSGGGGS	SEQ ID NO: 45
Isatuximab heavy chain	QVQLVQSGAEVAKPGTSVKLSCKASGYTFTDYWMQ WVKQRPGQGLEWIGTIYPGDGDTGYAQKFQGKATL TADKSSKTVYMHLSSLASEDSAVYYCARGDYYGSN SLDYWGQGTSTVTVSSASTKGPSVFPLAPSSKSTSGGT AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVD KKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD TLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM HEALHNHYTQKSLSLSPGK	SEQ ID NO: 30
Isatuximab light chain	DIVMTQSHLSMSTSLGDPVSITCKASQDVSTVVAWY QQKPGQSPRRLIYSASYRYIGVPDRFTGSGAGTDFTF TISSVQAEDLAVYYCQQHYSPPYTFGGGTKEIKRTV AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ WKVDNALQSGNSQESVTEQDSKIDSTYLSSTLTLSK ADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	SEQ ID NO: 31
Human IgG1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDV DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI EKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS LSPGK	SEQ ID NO: 43
Human IgG4	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCP APEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVDV QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTI SKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGF YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSR LTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLS LGK	SEQ ID NO: 44

8/27

FIG. 5

Name	Amino Acid Sequence
HC1 polypeptide sequence (F11A VH, IgG4 Fc CH3 knob)	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVR QAPGKEREWVAVISDDGSNKYYADSVKGRFTISRDNK NTLYLQMNSLRVEDTAVYYCAKDRGTMRVVYDTLDI WGQGTLLTVSSASTKGPSVFPLAPCSRSTSESTAALGCL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS VVTVPSSSLGTQTYTCNVDHKPSNTKVDKRVESKYGPP CPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAK GQPREPQVYTLPPSQEEMTKNQVSLWCLVKGFYPSDIA VEWESNGQPENNYKTPPVLDSDGSFFLYSRLTVDKSR WQEGNVFSCSVMEALHNHYTQKSLSLSLGK (SEQ ID NO: 46)
HC2 polypeptide sequence (F12A HCO VH, IgG4 Fc CH3 hole)	GVQLVESGGGLVQPGGSLRLSCTASGFTFSSSWMSWVR QAPGKGLEWVANIKQDGSEKDYVDSAKGRFTISRDNK NSLYLQMNNLRAEDTAVYYCARDRRGPFFHIWGQGTLL TVSSSESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGL PSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLSCA VKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLV SRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLSL GK (SEQ ID NO: 47)
LC1 (VL, Kappa light chain)	EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQK PGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISLQS EDFAVYYCQQYNNWPWTFGQGTKVEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACE VTHQGLSPVTKSFNRGEC (SEQ ID NO: 48)
LC1 CDR1	QSVSSN (SEQ ID NO: 49)
LC1 CDR2	GAS (SEQ ID NO: 50)
LC1 CDR3	QQYNNWPWT (SEQ ID NO: 51)
LC1 VL	EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQK PGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISLQS EDFAVYYCQQYNNWPWTFGQGTKVEIK (SEQ ID NO: 52)

SUBSTITUTE SHEET (RULE 26)

9/27




FIG. 6

10/27




FIG. 7

11/27






FIG. 8

12/27

FIG. 9



13/27




	EC50 [nM]	% Max Cell Death
CD38F12A_2GS_CD38F11A_IgG1	0.03	18.63
CD38F11A_2GS_CD38F12A_IgG1	0.29	18.46
CD38F12A_2GS_CD38F11A_IgG1sil	0.31	14.01
CD38F11A_2GS_CD38F12A_IgG1sil	0.11	14.55
CD38F12A_2GS_CD38F11A_IgG4sil	10.05	10.22
CD38F11A_2GS_CD38F12A_IgG4sil	0.08	18.87
CD38F11A + CD38F12A	736.60	4.48
Positive Control	0.15	63.25


FIG. 10

14/27

FIG. 11



15/27




	EC50 [nM]	% Max Inhibition
CD38F12A_2GS_CD38F11A_IgG1	6.3	83.6
CD38F11A_2GS_CD38F12A_IgG1	4.5	86.0
CD38F12A_2GS_CD38F11A_IgG1sil	5.0	83.3
CD38F11A_2GS_CD38F12A_IgG1sil	5.7	85.5
CD38F12A_2GS_CD38F11A_IgG4sil	6.0	81.4
CD38F11A_2GS_CD38F12A_IgG4sil	8.7	86.1
CD38F11A + CD38F12A	24.2	79.9

FIG. 12


16/27

FIG. 13



17/27

FIG. 14



18/27

FIG. 15






FIG. 16



20/27

FIG. 17



21/27

FIG. 18

	Enzyme Inhibition	Cell Binding	Apoptosis
Bivalent IgG1	+++++	+++++	ND
Tetravalent IgG1	+++++	ND	-
SiI-IgG4 Tetravalent	+++++	ND	-
SiI-IgG4 Bivalent	+++++	+++++	-
SiI-IgG4 Bivalent Triple Chain	+++++	+++++	-
SiI-IgG1 Tetravalent	+++++	++++	-
SiI-IgG1 Bivalent	+++++	+++++	-
Isatuximab	++++	+++++	+++++
Daratumumab	-	+++++	+++++



IgG4 Bivalent TC




IgG Bivalent



IgG Tetravalent

22/27

FIG. 19







FIG. 20


24/27

FIG. 21




Cell Line	EC50 [nM]	Max Inhibition (%)
Ramos	3.3	60
Daudi	1.6	57
CHO HuCD38	29.2	61

FIG. 22



26/27

FIG. 23



SUBSTITUTE SHEET (RULE 26)

27/27




FIG. 24